Live Breaking News & Updates on Nasdaq Mygn

Stay updated with breaking news from Nasdaq mygn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Federated Hermes Inc. Sells 1,533 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Federated Hermes Inc. decreased its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 2.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,009 shares of the company’s stock after selling 1,533 shares during the quarter. […] ....

United States , New Zealand General , New Zealand , Goldman Sachs Group , Qube Research Technologies Ltd , Invesco Ltd , Wellington Management Group , Deutsche Bank , Genetics Inc , Jump Financial , Hermes Inc , Exchange Commission , Federated Hermes , Myriad Genetics , Free Report , Management Group , Technologies Ltd , Genetics Stock Down , Get Free Report , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Visit Holdingschannel , Myriad Genetics Daily , Nasdaq Mygn , Sec Filings ,

Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Rating of "Hold" by Brokerages

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have received an average recommendation of “Hold” from the six analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. […] ....

United States , New Zealand General , New Zealand , Sei Investments Co , Wellington Management Group , Genetics Company Profile , Genetics Inc , Earnest Partners , Goldman Sachs Group , Glenview Capital Management , Vanguard Group Inc , Myriad Genetics , Get Free Report , Genetics Stock Down , Capital Management , Management Group , Get Free , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn ,

Brokerages Set Myriad Genetics, Inc. (NASDAQ:MYGN) Price Target at $23.17

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have been given an average rating of “Hold” by the six brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to […] ....

Hong Kong , United States , Tower Research Capital , Goldman Sachs Group , Genetics Company Profile , Hong Kong Ltd , Royal Bank , China Universal Asset Management Co , Genetics Inc , Myriad Genetics , Get Free Report , Genetics Trading Down , Universal Asset Management , Kong Ltd , Research Capital , Get Free , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn ,

Myriad Genetics (NASDAQ:MYGN) Releases Earnings Results, Beats Expectations By $0.03 EPS

Myriad Genetics (NASDAQ:MYGN – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.03, Briefing.com reports. The business had revenue of $196.60 million for the quarter, compared to analysts’ expectations of $194.80 million. Myriad Genetics had […] ....

Hong Kong , United States , Piper Sandler , Wolfe Research , Tower Research Capital , Wells Fargo Company , Us Bancorp , Jpmorgan Chase Co , Royal Bank , Goldman Sachs Group , Genetics Company Profile , Hong Kong Ltd , Genetics Inc , Myriad Genetics , Get Free Report , Research Capital , Kong Ltd , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn ,

Myriad Genetics (NASDAQ:MYGN) Releases FY 2024 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.000-0.050 for the period, compared to the consensus estimate of -0.010. The company issued revenue guidance of $820.0 million-$840.0 million, compared to the consensus revenue estimate of […] ....

New Zealand General , New Zealand , United States , Piper Sandler , America Corp , Goldman Sachs Group , Wellington Management Group , Vanguard Group Inc , Wells Fargo Company , Wolfe Research , Genetics Company Profile , Nuveen Asset Management , Genetics Inc , Myriad Genetics , Get Free Report , Management Group , Street Corp , Asset Management , Myrisk Hereditary Cancer Test , Germline Companion Diagnostic Test , Companion Diagnostic Test , Myriad Genetics Daily , Nasdaq Mygn ,